Cardiff, UK – August 9th 2012 – The EKF Diagnostics Group’s recent attendance at the AACC Clinical Lab Expo 2012 at the Los Angeles Convention Center, California highlighted the positive clinical support of their range of IVD solutions to monitor and diagnose diabetes and ketosis.
Renowned point-of-care expert, Dr James Nichols, Professor of Pathology at Tufts University School of Medicine, Boston, and Medical Director of Clinical Chemistry for Baystate Health in Springfield, Massachusetts, demonstrated the clinical efficacy of Beta-Hydroxybutyrate (?-HB) to measure the main ketone produced during ketosis. In his well-attended symposium on “The value, efficacy and efficiency of Beta-Hydroxybutyrate”, Dr Nichols showed how ?-HB testing is rapid and more specific than urine nitroprusside testing for ketones, providing quantitative results, which can be used to identify ketosis in multiple settings. The symposium illustrated how the rapid identification of ketosis through ?-HB testing can improve clinical management and patient care.
Delegates attending the expo also had their first chance to view two new PoC analysers for near-patient measurement and monitoring of HbA1c - EKF Diagnostics’ Quo-Test and Quo-Lab. 1,000 units of Quo-Test, which is currently pending US FDA approval, are already in use globally; its success a result of its accuracy, rapidity and simplicity. It is ideal for the physician’s office, providing results in less than four minutes. The Quo-Lab analyser, which uses the same methodology as the Quo-Test within an even more compact casing, is specifically designed for developing markets, with a four-step testing procedure that makes it a very cost effective and easy-to-use option for small laboratories and diabetes clinics.
According to Julian Baines, EKF Diagnostics Group CEO, “This years’ AACC expo was a tremendous success for our company and marked the first time Stanbio Laboratory and its parent company EKF Diagnostics exhibited together. The expo and the symposium showed delegates the range of in vitro diagnostic solutions the EKF Group can provide clinicians that greatly improve their diagnosis and treatment of patients.
We’re grateful to Dr Nichols for his presentation which highlighted why ß-Hydroxybutyrate has proved itself to be the gold standard in testing for diabetic ketoacidosis. An increasing number of renowned and respected diabetes and endocrinology hospitals in the United States have chosen our ?-HB LiquiColor reagent and our objective now is get that message out to the rest of the world.”
For more information please visit www.ekfdiagnostics.com and www.stanbio.com
About EKF Diagnostics Holdings plc
The EKF Diagnostics Group is a worldwide IVD business with expertise across the entire in vitro diagnostics chain, from fermentation and enzyme production, to the manufacture of liquid reagents, the design and building of world-class diagnostic devices and the distribution of rapid test kits for infectious diseases and pregnancy. The EKF range of analysers are a trusted brand in GP surgeries, pharmacies, blood banks, sports clinics, hospitals and laboratories for the measurement of glucose, lactate, haemoglobin, haematocrit and HbA1c.
The EKF Diagnostics Group has distributors in more than 70 locations around the globe. EKF Diagnostics’ strengths lie in its multi-national research and manufacturing facilities, teams of experienced analysts and engineers in Germany, Ireland, USA and the UK, and a board led by some of world’s foremost authorities in medical diagnostics.
EKF Diagnostics Holdings plc includes wholly owned subsidiaries including Quotient Diagnostics Limited, Argutus Medical and Stanbio Laboratory. Stanbio Laboratory (Boerne, Texas) is a fifty year old business with a heritage in clinical chemistry. It was acquired in June 2011 as part of EKF’s strategy to grow its presence in North, Central and South America.